Gut Receptor May Link Sleep Apnea to Heart Disease Risk
Sleep apnea is a well-established risk factor for cardiovascular disease, but the mechanisms behind this connection have remained unclear. New research published in Science Daily reveals a surprising gut-heart pathway that may help explain the link.
The Gut-Heart Connection
In a study conducted on mice, scientists found that disabling a bile acid receptor known as FXR (farnesoid X receptor) dramatically reduced arterial plaque buildup. This suggests that gut-based chemical signals may play a significant role in driving cardiovascular damage in people with sleep apnea.
The FXR receptor is involved in regulating bile acid metabolism and is expressed in various tissues including the gut and liver. When researchers inhibited this receptor, they observed a marked reduction in atherosclerosis development, pointing to its role in the inflammatory processes that connect sleep apnea to heart disease.
Implications for Treatment
These findings open the door to potential new therapeutic approaches that target gut microbes and their chemical signals rather than addressing sleep apnea directly. Modulating the gut microbiome or FXR activity could potentially reduce cardiovascular risk in patients who struggle to tolerate standard sleep apnea treatments like CPAP machines.
The research highlights how complex the relationship between sleep disorders and systemic disease can be, and how the gut microbiome may serve as an unexpected mediator of cardiovascular risk.